Video

Episode 2 - Elucidating the Patient's Starting Point in Care

The clinical paradigm for multiple sclerosis (MS) has witnessed an important shift in recent years, and those dynamics can be attributed to the advent of disease-modifying therapies (DMTs), increased awareness, and the conceptual evolution of MS becoming a treatable disease that requires early and effective intervention to better control the damage process caused by MS. Admittedly, while more patients with MS may be entering the health system through specialist referrals and neurologists, improved diagnostic modalities, such as the advances in neurology and neuro-imaging via MRI scan, arguably still does not explain the increased incidence of MS, and unfortunately, diagnosis of the disease is still not occurring early enough.


Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Cathy Eng, MD, FACP, FASCO
Leigh Maria Ramos-Platt, MD
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo